When our M&A advisory team at a bulge bracket firm first explored generative AI capabilities in 2024, we treated it like any other technology pilot—assign a task force, run proof-of-concept models, measure ROI. Within six months, that approach had failed spectacularly. We learned the hard way that Enterprise GenAI Deployment demands a fundamentally different playbook than traditional enterprise software rollouts, especially in an environment governed by stringent regulatory frameworks and where analytical precision directly impacts billion-dollar decisions. The turning point came when we reframed our strategy around real business pain points rather than technology capabilities. Instead of asking what GenAI could theoretically do, we examined where our equity research analysts were spending eighty-hour weeks and where our compliance teams were drowning in regulatory reporting backlogs. That shift in perspective transformed our Enterprise GenAI Deployment from a technology experimen...